A Phase 2/3 interventional study of Placebo Oral Tablet and AGB101 220 mg tablet in Mild Cognitive Impairment and Prodromal Alzheimer's Disease, sponsored by AgeneBio. Completed at 24 sites in 2 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-17.
Sponsored by AgeneBio · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,420 studies in Cognitive Dysfunction with a site in United States — 329 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.
Among the 1,420 studies in Cognitive Dysfunction with a site in United States, this one is the 225th largest by enrollment of the 1,145 interventional ones that give a count, is one of 84 that started in 2018, is one of 12 in phase 2/3, and was the 549th registered.
3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.
Browse Cognitive Dysfunction studies →329 of the 1,420 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 50–100 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 65+
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,420 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 126 · Phase 2 234 · Phase 3 54 · Phase 4 58
First in 1993; this study’s year is marked. 84 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 64 across 2,799 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 59 across the 1,145 interventional studies, 150 across the 270 observational. Of the 887 that completed or were terminated, 378 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,420 have an industry lead sponsor. The 10 most frequent:
AgeneBio is the lead sponsor of 2 studies on the registry; none are open to participants now.
AgeneBio has 2 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
175 of the studies in Cognitive Dysfunction with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT06950190Phase 3Ellis MedicineEvaluating Cognitive Changes on Patients in Chemotherapy (ECCPC) | 2027-02-20 |
| NCT03560960Boston UniversityMulti-Center Development of a Novel Diagnostic Test for Alzheimer's Disease | 2026-11 |
Add all 175 to your calendar (.ics) → With an account.
Among the 1,420 studies in Cognitive Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects between 55 and 85 years old (inclusive) in good general health:
Have MCI due to AD as defined by all of the following criteria and consistent with the National Institute on Aging-Alzheimer's Association criteria:
Permitted medications:
Willing and able to undergo imaging procedures:
A Positron Emission Tomography (PET) scan with Florbetaben(an 18F isotope diagnostic agent) or documented evidence of an amyloid positive PET scan.
The Florbetaben scan performed at baseline must be read by a qualified physician with experience in reading amyloid PET scans, and it should be consistent with the presence of amyloid plaques.
Exclusion Criteria:
Participation in a therapeutic clinical study for any medical or psychiatric indications within 3 months (6 months for biologics) of the screening visit, or at any time during the study.
Subjects must understand that they may only enroll in this clinical study once; they may not enroll in any other clinical study while participating in the current study, and they may not participate in a clinical study of a drug, biologic, therapeutic device, or medical food, in which the last dose/administration was received within 3 months (6 months for biologics) prior to screening.
Diagnosis of major depression or bipolar disorder, as described in the , 5th Ed (DSM-5), within the past 3 years.
Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol. Subjects must not have a major depressive disorder or other types of depression that could confound diagnosis of MCI due to AD, or clinical assessments, in the opinion of the investigator. The geriatric depression scale (long form score >9 suggests depression) results should be reviewed by the investigator to assist in this determination.
abnormalities in B12 or thyroid function test that might interfere with the study.
A low B12 (below normative range for elderly) is exclusionary, unless follow-up labs (homocysteine and methylmalonic acid) indicate that it is not physiologically significant. If the B12 deficiency is treated, subjects may become eligible to participate in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
Drug: Placebo Oral Tablet
Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
Drug: AGB101 220 mg tablet
Placebo oral tablet
220 mg AGB101 active compound
Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline
CDR-SB scores at baseline were subtracted from CDR-SB scores at week 78 to generate the change score from baseline, with a possible total range of -18 to 18. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78.
Time frame: 78 weeks
Change in Mini Mental Status Exam (MMSE) Score From Baseline
MMSE scores at baseline were subtracted from MMSE scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect improved performance on the MMSE at week 78, while negative change scores reflect worsening performance on the MMSE at week 78.
Time frame: 78 weeks
Change in Functional Activities Questionnaire (FAQ) Score From Baseline
FAQ scores at baseline were subtracted from FAQ scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect greater impairment on the FAQ at week 78, while negative change scores reflect less impairment on the FAQ at week 78.
Time frame: 78 weeks
| Milestone | Placebo Oral Tablet | AGB101 220 mg Tablet |
|---|---|---|
| Started | 83 | 81 |
| Completed | 66 | 55 |
| Not completed | 17 | 26 |
CDR-SB scores at baseline were subtracted from CDR-SB scores at week 78 to generate the change score from baseline, with a possible total range of -18 to 18. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78.
| score on a scale | Placebo Oral Tablet | AGB101 220 mg Tablet |
|---|---|---|
| Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline | 1.1 ± 2 | .9 ± 1.5 |
MMSE scores at baseline were subtracted from MMSE scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect improved performance on the MMSE at week 78, while negative change scores reflect worsening performance on the MMSE at week 78.
| units on a scale | Placebo Oral Tablet | AGB101 220 mg Tablet |
|---|---|---|
| Change in Mini Mental Status Exam (MMSE) Score From Baseline | -1.9 ± 3.7 | -2.2 ± 2.8 |
FAQ scores at baseline were subtracted from FAQ scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect greater impairment on the FAQ at week 78, while negative change scores reflect less impairment on the FAQ at week 78.
| units on a scale | Placebo Oral Tablet | AGB101 220 mg Tablet |
|---|---|---|
| Change in Functional Activities Questionnaire (FAQ) Score From Baseline | 3.6 ± 6.4 | 4 ± 5.3 |
Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Oral Tablet | 0/83 (0%) | 10/83 (12%) | 49/83 (59%) |
| AGB101 220 mg Tablet | 2/78 (2.6%) | 13/78 (16.7%) | 40/78 (51.3%) |
| Event | Placebo Oral Tablet | AGB101 220 mg Tablet |
|---|---|---|
| Sinus node dysfunctionCardiac disorders | 0/83 | 3/78 |
| SeizureNervous system disorders | 1/83 | 2/78 |
| Hip fractureInjury, poisoning and procedural complications | 2/83 | 0/78 |
| Atrial fibrillationCardiac disorders | 0/83 | 1/78 |
| Atrioventricular block second degreeCardiac disorders | 0/83 | 1/78 |
| Coronary artery diseaseCardiac disorders | 0/83 | 1/78 |
| AppendicitisInfections and infestations | 0/83 | 1/78 |
| CystitisInfections and infestations | 0/83 | 1/78 |
| HypoglycemiaMetabolism and nutrition disorders | 0/83 | 1/78 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/83 | 1/78 |
| Event | Placebo Oral Tablet | AGB101 220 mg Tablet |
|---|---|---|
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 20/83 | 11/78 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 15/83 | 12/78 |
| Nervous system disordersNervous system disorders | 15/83 | 8/78 |
| Psychiatric disordersPsychiatric disorders | 9/83 | 14/78 |
| Gastrointestinal disordersGastrointestinal disorders | 13/83 | 7/78 |
| Infections and infestationsInfections and infestations | 13/83 | 11/78 |
| General disorders and administration site conditionGeneral disorders | 10/83 | 5/78 |
| InvestigationsInvestigations | 8/83 | 7/78 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 7/83 | 2/78 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 7/83 | 2/78 |
| Age, Continuous(years) | Placebo Oral Tablet | AGB101 220 mg Tablet | Total |
|---|---|---|---|
| Mean | 73.1 ± 7 | 72.2 ± 6.7 | 72.7 ± 6.9 |
| Sex: Female, Male(Participants) | Placebo Oral Tablet | AGB101 220 mg Tablet | Total |
|---|---|---|---|
| Female | 40 | 32 | 72 |
| Male | 43 | 49 | 92 |
| Race (NIH/OMB)(Participants) | Placebo Oral Tablet | AGB101 220 mg Tablet | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 5 | 7 |
| White | 81 | 75 | 156 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Clinical Dementia Rating-Sum of Boxes (CDR-SB)(units on a scale) | Placebo Oral Tablet | AGB101 220 mg Tablet | Total |
|---|---|---|---|
| Mean | 2.7 ± 1.1 | 2.7 ± 1 | 2.7 ± 1 |
| Mini Mental Status Exam (MMSE)(units on a scale) | Placebo Oral Tablet | AGB101 220 mg Tablet | Total |
|---|---|---|---|
| Mean | 26 ± 2.2 | 26.2 ± 2.1 | 26.1 ± 2.1 |
| Functional Activities Questionnaire (FAQ)(units on a scale) | Placebo Oral Tablet | AGB101 220 mg Tablet | Total |
|---|---|---|---|
| Mean | 7.0 ± 5.2 | 7.6 ± 5.5 | 7.3 ± 5.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Nov 2022, 46 months.
Results were first posted in May 2024, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam
AgeneBio